Mirum Pharmaceuticals vs Tarsus Pharmaceuticals
MIRM and TARS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MIRM and TARS compare
Mirum Pharmaceuticals is the larger company, worth 1.7 times as much as Tarsus Pharmaceuticals ($5.5B against $3.3B).
Tarsus Pharmaceuticals grew revenue faster over the last twelve months (105% versus 44.0% for Mirum Pharmaceuticals).
Tarsus Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −7.7% compared with −139% at Mirum Pharmaceuticals.
Tarsus Pharmaceuticals scores higher on the StockData Score (11 against 5 for Mirum Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MIRM | TARS |
|---|---|---|
| Size and price | ||
| Market cap | $5.5B | $3.3B |
| Share price | $85.00 | $74.85 |
| Change, 1 year | 20.6% | 10.9% |
| Change, 5 years | 424% | 169% |
| Beta (5Y) | 0.67 | 0.63 |
| Employees | 372 | 370 |
| StockData Score | ||
| Total score | 5 | 11 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 3 | 3 |
| Performance score | 1 | 3 (better) |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 8.9× | 5.4× (better) |
| P/B | – | 9.5× |
| P/FCF | – | 58.7× |
| FCF yield | −4.1% | 1.7% (better) |
| Fair value | – | $75.56 |
| Margin of safety | – | 0.94% |
| Growth | ||
| Revenue growth (TTM) | 44.0% | 105% (better) |
| Profitability | ||
| Operating margin | −135% | −8.0% (better) |
| Net margin | −139% | −7.7% (better) |
| FCF margin | −37.0% | 9.2% (better) |
| Return on equity | −703% | −13.7% (better) |
| Financial health | ||
| Debt / equity | – | 0.21 |
| Interest coverage | −62.1× | −5.5× (better) |
| Current ratio | 2.86 | 3.20 (better) |
| Altman Z-score | −0.47 | 7.91 (better) |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 110% | 110% |
| Held by insiders | 9.2% | 3.1% |
| Insider net buying, 12 months | −$33.2M | −$20.0M (better) |
| Short interest, % of float | 11.8% | 14.3% |
Go deeper
- MIRM stock overview
- MIRM income statement
- MIRM valuation and score
- TARS stock overview
- TARS income statement
- TARS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.